Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Protalix ( (PLX) ) just unveiled an announcement.
On January 30, 2026, Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every‑four‑weeks dosing regimen of Elfabrio for adult Fabry disease patients who are stable on enzyme replacement therapy. The opinion, based on long‑term clinical data including the BRIGHT study and its extension, will now be reviewed by the European Commission, and if approved is expected to significantly reduce treatment burden by extending infusion intervals, potentially improving quality of life for eligible patients while also positioning Protalix and Chiesi more strongly in the Fabry disease market and triggering a $25 million regulatory milestone payment to Protalix.
The most recent analyst rating on (PLX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
The score is driven primarily by improved profitability and a healthier balance sheet, but is held back by deteriorating TTM cash flow and shrinking revenue. Earnings-call updates were supportive (strong YTD revenue growth, positive quarterly income, adequate near-term cash) while technicals are modestly positive and valuation remains somewhat demanding.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet medical needs, leveraging its proprietary ProCellEx manufacturing platform and working with partners such as Chiesi Global Rare Diseases to deliver enzyme replacement therapies like Elfabrio (pegunigalsidase alfa) for Fabry disease.
Average Trading Volume: 657,843
Technical Sentiment Signal: Buy
Current Market Cap: $165.7M
For a thorough assessment of PLX stock, go to TipRanks’ Stock Analysis page.